Royal Bank of Canada’s Astria Therapeutics ATXS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-1,187
| Closed | -$15K | – | 7094 |
|
|
2025
Q4 | $15K | Sell |
1,187
-104,433
| -99% | -$1.25M | ﹤0.01% | 6190 |
|
|
2025
Q3 | $768K | Buy |
105,620
+29,004
| +38% | +$196K | ﹤0.01% | 4182 |
|
|
2025
Q2 | $410K | Buy |
76,616
+76,554
| +123,474% | +$371K | ﹤0.01% | 4622 |
|
|
2025
Q1 | $0 | Sell |
62
-3,211
| -98% | -$22.5K | ﹤0.01% | 6794 |
|
|
2024
Q4 | $29K | Sell |
3,273
-1,883
| -37% | -$20K | ﹤0.01% | 5939 |
|
|
2024
Q3 | $56K | Buy |
5,156
+920
| +22% | +$10.2K | ﹤0.01% | 5643 |
|
|
2024
Q2 | $39K | Buy |
4,236
+3,120
| +280% | +$30.5K | ﹤0.01% | 5764 |
|
|
2024
Q1 | $16K | Sell |
1,116
-11,434
| -91% | -$142K | ﹤0.01% | 5998 |
|
|
2023
Q4 | $96K | Buy |
12,550
+8,917
| +245% | +$49.3K | ﹤0.01% | 5644 |
|
|
2023
Q3 | $27K | Buy |
3,633
+998
| +38% | +$8.51K | ﹤0.01% | 6070 |
|
|
2023
Q2 | $22K | Buy |
+2,635
| New | +$30.4K | ﹤0.01% | 6158 |
|
|
2022
Q2 | – | Sell |
-145
| Closed | -$1K | – | 7353 |
|
|
2022
Q1 | $1K | Buy |
145
+80
| +123% | +$476 | ﹤0.01% | 7565 |
|
|
2021
Q4 | $0 | Hold |
65
| – | – | ﹤0.01% | 7638 |
|
|
2021
Q3 | $1K | Sell |
65
-254
| -80% | -$2.43K | ﹤0.01% | 7446 |
|
|
2021
Q2 | $4K | Sell |
319
-122
| -28% | -$1.58K | ﹤0.01% | 7108 |
|
|
2021
Q1 | $7K | Buy |
441
+154
| +54% | +$2.78K | ﹤0.01% | 6929 |
|
|
2020
Q4 | $3K | Buy |
287
+272
| +1,813% | +$4.85K | ﹤0.01% | 6778 |
|
|
2020
Q3 | $1K | Hold |
15
| – | – | ﹤0.01% | 6389 |
|
|
2020
Q2 | $1K | Hold |
15
| – | – | ﹤0.01% | 6380 |
|
|
2020
Q1 | $0 | Sell |
15
-1
| -6% | -$31 | ﹤0.01% | 6650 |
|
|
2019
Q4 | $1K | Sell |
16
-16
| -50% | -$504 | ﹤0.01% | 6625 |
|
|
2019
Q3 | $1K | Buy |
32
+17
| +113% | +$672 | ﹤0.01% | 6401 |
|
|
2019
Q2 | $1K | Hold |
15
| – | – | ﹤0.01% | 6672 |
|
|
2019
Q1 | $1K | Hold |
15
| – | – | ﹤0.01% | 6610 |
|
|
2018
Q4 | $0 | Sell |
15
-1
| -6% | -$38 | ﹤0.01% | 6731 |
|
|
2018
Q3 | $1K | Buy |
16
+1
| +7% | +$45 | ﹤0.01% | 6582 |
|
|
2018
Q2 | $1K | Hold |
15
| – | – | ﹤0.01% | 6330 |
|
|
2018
Q1 | $2K | Sell |
15
-167
| -92% | -$16.7K | ﹤0.01% | 6099 |
|
|
2017
Q4 | $16K | Buy |
182
+15
| +9% | +$1.76K | ﹤0.01% | 5682 |
|
|
2017
Q3 | $21K | Buy |
+167
| New | +$13.9K | ﹤0.01% | 5916 |
|
|
2015
Q4 | – | Sell |
-3
| Closed | -$2K | – | 6622 |
|
|
2015
Q3 | $2K | Buy |
+3
| New | +$2.14K | ﹤0.01% | 6368 |
|
Royal Bank of Canada's ATXS Position: Q1 2026 in Review
Royal Bank of Canada sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 1,187 shares — an estimated $15K sold.
Royal Bank of Canada first reported a position in ATXS in Q3 2015 and held it in 31 quarters. The position peaked at $768K in Q3 2025. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.
- Royal Bank of Canada reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
- Royal Bank of Canada sold 1,187 Astria Therapeutics shares in Q1 2026, an estimated $15K.
- Royal Bank of Canada first reported a position in Astria Therapeutics in Q3 2015 and held it in 31 quarters.
- Royal Bank of Canada's Astria Therapeutics position peaked at $768K in Q3 2025.
- 0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.
Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.